{"nctId":"NCT04537793","briefTitle":"Evaluation of ELX/TEZ/IVA in Cystic Fibrosis (CF) Subjects 2 Through 5 Years","startDateStruct":{"date":"2020-11-19","type":"ACTUAL"},"conditions":["Cystic Fibrosis"],"count":83,"armGroups":[{"label":"Part A: ELX/TEZ/IVA","type":"EXPERIMENTAL","interventionNames":["Drug: ELX/TEZ/IVA","Drug: IVA"]},{"label":"Part B: ELX/TEZ/IVA","type":"EXPERIMENTAL","interventionNames":["Drug: ELX/TEZ/IVA","Drug: IVA"]}],"interventions":[{"name":"ELX/TEZ/IVA","otherNames":["VX-445/VX-661/VX-770","elexacaftor/tezacaftor/ivacaftor"]},{"name":"IVA","otherNames":["VX-770","ivacaftor"]}],"eligibilityModule":{"eligibilityCriteria":"Key Inclusion Criteria:\n\n* Homozygous for the F508del mutation or heterozygous for F508del and a minimal function (MF) mutation (F/F or F/MF genotypes)\n\nKey Exclusion Criteria:\n\n* Clinically significant cirrhosis with or without portal hypertension\n* Lung infection with organisms associated with a more rapid decline in pulmonary status\n* Solid organ or hematological transplantation\n\nOther protocol defined Inclusion/Exclusion criteria may apply","healthyVolunteers":false,"sex":"ALL","minimumAge":"2 Years","maximumAge":"5 Years","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Part A: Observed Pre-dose Concentration (Ctrough) of ELX,TEZ,IVA, and Relevant Metabolites","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.00"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.44","spread":"2.09"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.69","spread":"2.11"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.00"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.39","spread":"1.65"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.47","spread":"1.65"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.00"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.86","spread":"1.07"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.85","spread":"1.10"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.00"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.42","spread":"1.42"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.68","spread":"1.52"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.00"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.702","spread":"0.503"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.746","spread":"0.526"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.00"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.78","spread":"0.990"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.91","spread":"0.990"}]}]}]},{"type":"PRIMARY","title":"Part A: Safety and Tolerability as Assessed by Number of Participants With Treatment- Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]},{"type":"PRIMARY","title":"Part B: Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"74","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Part B: Observed Pre-dose Plasma Concentration (Ctrough) of ELX,TEZ,IVA and Relevant Metabolites","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.91","spread":"1.38"},{"groupId":"OG001","value":"3.87","spread":"2.75"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.13","spread":"1.90"},{"groupId":"OG001","value":"3.56","spread":"2.19"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.48","spread":"1.65"},{"groupId":"OG001","value":"3.49","spread":"2.22"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.01","spread":"1.11"},{"groupId":"OG001","value":"3.18","spread":"2.19"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.85","spread":"1.12"},{"groupId":"OG001","value":"2.33","spread":"1.87"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.32","spread":"2.01"},{"groupId":"OG001","value":"2.22","spread":"1.66"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.48","spread":"1.27"},{"groupId":"OG001","value":"2.17","spread":"1.69"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.73","spread":"0.828"},{"groupId":"OG001","value":"1.94","spread":"1.58"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.73","spread":"0.666"},{"groupId":"OG001","value":"2.14","spread":"1.72"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.62","spread":"0.716"},{"groupId":"OG001","value":"1.79","spread":"0.947"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.60","spread":"0.951"},{"groupId":"OG001","value":"1.76","spread":"1.10"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.52","spread":"0.701"},{"groupId":"OG001","value":"1.80","spread":"1.42"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.07","spread":"1.08"},{"groupId":"OG001","value":"7.07","spread":"2.11"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.80","spread":"1.64"},{"groupId":"OG001","value":"7.09","spread":"2.18"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.06","spread":"2.37"},{"groupId":"OG001","value":"7.18","spread":"2.38"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.88","spread":"1.94"},{"groupId":"OG001","value":"6.95","spread":"2.77"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.549","spread":"0.373"},{"groupId":"OG001","value":"0.661","spread":"0.552"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.535","spread":"0.402"},{"groupId":"OG001","value":"0.594","spread":"0.405"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.383","spread":"0.203"},{"groupId":"OG001","value":"0.530","spread":"0.474"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.483","spread":"0.347"},{"groupId":"OG001","value":"0.580","spread":"0.511"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.47","spread":"0.969"},{"groupId":"OG001","value":"1.67","spread":"0.961"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.64","spread":"1.29"},{"groupId":"OG001","value":"1.52","spread":"0.737"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.19","spread":"0.602"},{"groupId":"OG001","value":"1.45","spread":"0.907"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.24","spread":"0.673"},{"groupId":"OG001","value":"1.51","spread":"0.911"}]}]}]},{"type":"SECONDARY","title":"Part B: Absolute Change in Sweat Chloride (SwCl)","description":"Sweat samples were collected using an approved collection device.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-57.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Part B: Absolute Change in Lung Clearance Index 2.5 (LCI 2.5)","description":"The LCI2.5 index is the number of lung turnovers required to reduce the end tidal inert gas concentration to 1/40th of its starting values and is calculated by dividing the sum of exhaled tidal breaths (cumulative exhaled volume (CEV)) by simultaneously measured functional residual capacity (FRC). An LCI of 7.5 and below is normal; values greater than 7.5 are abnormal. LCI is able to detect abnormalities in lung function earlier than more traditional modalities such as spirometry.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.83","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":18},"commonTop":["Cough","Rhinorrhoea","Pyrexia","Vomiting","COVID-19"]}}}